Clarivate’s Epidemiology’s coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CLBP…
Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key NBP patient populations covering 171 countries and more than 99% of…
Since 2018, four novel calcitonin gene-related peptide (CGRP)-targeting monoclonal antibodies (MAbs)—Novartis / Amgen’s Aimovig, Eli Lilly’s Emgality, Teva’s Ajovy, and Lundbeck’s Vyepti…
Epidemiology Data Slicer – Multiple Sclerosis
Epidemiology Data Slicer – Type 2 Diabetes
Epidemiology Data Slicer- Non-Hodgkin’s Lymphoma